Recombinant multi-species ATP2A1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ATP2A1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes one of the SERCA Ca(2+)-ATPases, which are intracellular pumps located in the sarcoplasmic or endoplasmic reticula of muscle cells. This enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen, and is involved in muscular excitation and contraction. Mutations in this gene cause some autosomal recessive forms of Brody disease, characterized by increasing impairment of muscular relaxation during exercise. Alternative splicing results in three transcript variants encoding different isoforms. [provided by RefSeq, Oct 2013]
The Alternative Names of target: ATP2A,ATP2A1,Atp2a1,Calcium pump 1,Calcium-transporting ATPase sarcoplasmic reticulum type,Endoplasmic reticulum class 1/2 Ca(2+) ATPase,SERCA1,SR Ca(2+)-ATPase 1,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,Serca1,fast twitch skeletal muscle isoform
Go
to ATP2A1 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP0387-Ag-1/ GM-Tg-hg-IP0387-Ag-2 | Human ATP2A1 protein | Human |
| GM-Tg-rg-IP0387-Ag-1/ GM-Tg-rg-IP0387-Ag-2 | Rat ATP2A1 protein | Rat |
| GM-Tg-mg-IP0387-Ag-1/ GM-Tg-mg-IP0387-Ag-2 | Mouse ATP2A1 protein | Mouse |
| GM-Tg-cynog-IP0387-Ag-1/ GM-Tg-cynog-IP0387-Ag-2 | Cynomolgus/Rhesus macaque ATP2A1 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP0387-Ag-1/ GM-Tg-felg-IP0387-Ag-2 | Feline ATP2A1 protein | Feline |
| GM-Tg-cang-IP0387-Ag-1/ GM-Tg-cang-IP0387-Ag-2 | Canine ATP2A1 protein | Canine |
| GM-Tg-bovg-IP0387-Ag-1/ GM-Tg-bovg-IP0387-Ag-2 | Bovine ATP2A1 protein | Bovine |
| GM-Tg-equg-IP0387-Ag-1/ GM-Tg-equg-IP0387-Ag-2 | Equine ATP2A1 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP0387-Ag-1/ GM-Tg-hg-IP0387-Ag-2;
GM-Tg-rg-IP0387-Ag-1/ GM-Tg-rg-IP0387-Ag-2;
GM-Tg-mg-IP0387-Ag-1/ GM-Tg-mg-IP0387-Ag-2; GM-Tg-cynog-IP0387-Ag-1/ GM-Tg-cynog-IP0387-Ag-2; GM-Tg-felg-IP0387-Ag-1/ GM-Tg-felg-IP0387-Ag-2; GM-Tg-cang-IP0387-Ag-1/ GM-Tg-cang-IP0387-Ag-2; GM-Tg-bovg-IP0387-Ag-1/ GM-Tg-bovg-IP0387-Ag-2; GM-Tg-equg-IP0387-Ag-1/ GM-Tg-equg-IP0387-Ag-2 |
| Products Name | ATP2A1 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | ATP2A1 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ATP2A1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.